Verrica Pharmaceuticals Inc (STU:1NE0) Stock Price, Trades & News

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	14.29
Equity-to-Asset	0.41
Debt-to-Equity	0.09
Debt-to-EBITDA	-0.13
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-9.32	Distress Grey Safe
Beneish M-Score	3.42	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.1
	3-Year EBITDA Growth Rate	48.2
	3-Year EPS without NRI Growth Rate	37.6
	3-Year FCF Growth Rate	33.2
	3-Year Book Growth Rate	-47.1
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	45.84
	Future 3-5Y Total Revenue Growth Rate Estimate	35.27

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	17.13
	9-Day RSI	21.62
	14-Day RSI	23.7

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.1
	Quick Ratio	1.98
	Cash Ratio	1.27
	Days Inventory	215.55
	Days Sales Outstanding	68.42
	Days Payable	180.28

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-61.1
	Shareholder Yield %	30.18

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	89.52
	Operating Margin %	-36.39
	Net Margin %	-47.97
	EBITDA Margin %	-30.57
	FCF Margin %	-38.53
	OCF Margin %	-38.53
	ROA %	-42.83
	ROIC %	-56.41
	3-Year ROIIC %	118.76
	ROC (Joel Greenblatt) %	-625.49
	ROCE %	-68.97
	Moat Score	3
	Tariff Resilience Score	7

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	1.46
	PB Ratio	5.37
	Price-to-Tangible-Book	5.33
	EV-to-EBIT	-5.53
	EV-to-EBITDA	-5.9
	EV-to-Revenue	1.81
	EV-to-Forward-Revenue	2.73
	EV-to-FCF	-4.75
	Price-to-GF-Value	0.36
	Price-to-Net-Current-Asset-Value	7.63
	Earnings Yield (Greenblatt) %	-18.08
	FCF Yield %	-16.37

Financials (Next Earnings Date:2026-08-12 Est.)

Annual Quarterly TTM

STU:1NE0's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Verrica Pharmaceuticals Inc Executives

Details

GF Value™: €12.19

STU:1NE0

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 1NE0. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	31.928
	EPS (TTM) (€)	-0.885
	Beta	2.2184
	3-Year Sharpe Ratio	-0.54
	3-Year Sortino Ratio	-0.74
	Volatility %	32.79
	14-Day RSI	23.7
	14-Day ATR (€)	0.23102
	20-Day SMA (€)	5.128
	12-1 Month Momentum %	-
	52-Week Range (€)	4.42 - 5.87
	Shares Outstanding (Mil)	17.18

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Verrica Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Verrica Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-17 08:30	In 116 days
Third quarter earnings results for 2026	2026-11-17	In 115 days
Second quarter earnings conference call for 2026	2026-08-12 16:30	In 19 days
Second quarter earnings results for 2026	2026-08-12	In 18 days
General meeting for 2026	2026-06-05 10:00	5.81 (+0.00%)
Jefferies Global Healthcare Conference	2026-06-04 11:05	5.81 (+0.00%)
H.C. Wainwright 4th Annual BioConnect Investor Conference	2026-05-19 13:30	5.81 (+0.00%)
First quarter earnings conference call for 2026	2026-05-12 16:30	5.81 (+0.00%)
First quarter earnings results for 2026	2026-05-12	5.81 (+0.00%)
25th Annual Needham Virtual Healthcare Conference	2026-04-15 15:00	5.81 (+0.00%)

Show

Entries

Verrica Pharmaceuticals Inc Frequently Asked Questions

What is Verrica Pharmaceuticals Inc(STU:1NE0)'s stock price today?

The current price of STU:1NE0 is €4.43. The 52 week high of STU:1NE0 is €5.87 and 52 week low is €4.42.

When is next earnings date of Verrica Pharmaceuticals Inc(STU:1NE0)?

The next earnings date of Verrica Pharmaceuticals Inc(STU:1NE0) is 2026-08-12 Est..

Does Verrica Pharmaceuticals Inc(STU:1NE0) pay dividends? If so, how much?

Verrica Pharmaceuticals Inc(STU:1NE0) does not pay dividend.

Press Release

	Subject	Date
	VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm	2026-03-20
	VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. -- VRCA	2026-03-20
	Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. -- VRCA	2026-03-19
	Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights	2025-10-24
	VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	2024-10-11
	VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	2024-09-27
	VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	2024-09-13
	VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	2024-03-08
	VERRICA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	2024-02-23
	VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	2024-02-14

10/Page

Articles on Verrica Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.